septerna - Search News

News

Novo Nordisk Inks $2.2B Deal With Septerna

Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

The Wall Street Journal on MSN · 1d

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Reuters on MSN · 2d

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

PMLive8h

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

23h

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...

Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Novo Nordisk Inks $2.2B Deal With Septerna

Trending now